Stada in-licenses teriparatide biosimilar

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Stada in-licenses teriparatide biosimilar

Biosimilars/News | Posted 17/10/2014 0 Post your comment

German generics giant Stada Arzneimittel (Stada) announced on 13 October 2014 that it had made a deal to in-licensing a teriparatide biosimilar.

The teriparatide biosimilar is being developed by Richter-Helm BioTec and will be launched under the Stada label throughout Europe following expiration of the patent on the originator product Forteo (teriparatide).

Teriparatide is a recombinant form of parathyroid hormone. It is an effective anabolic, i.e. bone growing agent used in the treatment of some forms of osteoporosis. Sales of Eli Lilly’s blockbuster drug Forteo were US$1.2 billion for 2013.

Stada already markets a biosimilar in Europe, Silapo (epoetin zeta) [1] and has also in-licensed a biosimilar filgrastim product (Grastofil) from Canada-based Apotex [2]. Stada also made a deal with Hungary-based Gedeon Richter (Richter) in 2011 for biosimilars of two monoclonal antibody products, rituximab and trastuzumab, which are used to treat cancer and autoimmune diseases [3].

Stada has secured the license to market the teriparatide biosimilar in Europe and is preparing for a market launch in 2019. The company is also reportedly in talks over another biosimilar that could be introduced in 2017, but no deal has yet been struck.

No teriparatide biosimilars are yet marketed in Europe, however, several ‘similar biologics’ are already on the market in India [4].

Related articles
Stada in-licenses biosimilar filgrastim

Originator biologicals approved and marketed in Germany

References
1.   GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Oct 17]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
2.   GaBI Online - Generics and Biosimilars Initiative. Stada in-licenses biosimilar filgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Oct 17]. Available from: www.gabionline.net/Biosimilars/News/Stada-in-licenses-biosimilar-filgrastim
3.   GaBI Online - Generics and Biosimilars Initiative. Stada and Richter to collaborate on biosimilar development [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Oct 17]. Available from: www.gabionline.net/Biosimilars/News/Stada-and-Richter-to-collaborate-on-biosimilar-development
4.   GaBI Online - Generics and Biosimilars Initiative. ‘Similar biologics’ approved and marketed in India [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Oct 17]. Available from: www.gabionline.net/Biosimilars/General/Similar-biologics-approved-and-marketed-in-India

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Eli Lilly, Stada